Genethera Stock Current Valuation
| GTHR Stock | USD 0.0001 0.00 0.00% |
Valuation analysis of GeneThera helps investors to measure GeneThera's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that GeneThera's price fluctuation is very steady at this time. Calculation of the real value of GeneThera is based on 3 months time horizon. Increasing GeneThera's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the GeneThera pink sheet is determined by what a typical buyer is willing to pay for full or partial control of GeneThera. Since GeneThera is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GeneThera Pink Sheet. However, GeneThera's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of GeneThera's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GeneThera's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GeneThera helps investors to forecast how GeneThera pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GeneThera more accurately as focusing exclusively on GeneThera's fundamentals will not take into account other important factors: GeneThera Company Current Valuation Analysis
GeneThera's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current GeneThera Current Valuation | 1.44 M |
Most of GeneThera's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneThera is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, GeneThera has a Current Valuation of 1.44 M. This is 99.99% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
GeneThera Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneThera's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of GeneThera could also be used in its relative valuation, which is a method of valuing GeneThera by comparing valuation metrics of similar companies.GeneThera is currently under evaluation in current valuation category among its peers.
GeneThera Fundamentals
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Shares Owned By Insiders | 17.99 % | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Net Income | (1.01 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X | |||
| Cash Flow From Operations | (8.57 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | 0.89 | |||
| Market Capitalization | 533.53 K | |||
| Total Asset | 6.3 K | |||
| Retained Earnings | (25.59 M) | |||
| Working Capital | (7.03 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 7.08 M | |||
| Net Asset | 6.3 K |
About GeneThera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneThera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneThera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneThera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.